目的 探討骨疏康顆粒聯(lián)合鹽酸雷洛昔芬片治療絕經(jīng)后骨質(zhì)疏松癥的臨床療效。方法 選取2021年1月—2022年12月在漯河市郾城區(qū)中醫(yī)院就診的120例骨質(zhì)疏松癥患者，按照隨機(jī)數(shù)字表法將120例患者分為對(duì)照組和治療組，每組各60例。對(duì)照組患者口服鹽酸雷洛昔芬片，1片/次，1次/d。治療組患者在對(duì)照組治療的基礎(chǔ)上餐后溫水沖服骨疏康顆粒，1袋/次，3次/d。兩組患者連續(xù)治療3個(gè)月。觀察兩組的臨床療效，比較兩組自覺(jué)疼痛程度、股骨近端、橈尺骨的骨密度和血清骨鈣素（BGP）、Ⅰ型膠原C末端肽（CTX-1）、Ⅰ型前膠原氨基末端肽（PINP）、轉(zhuǎn)化生長(zhǎng)因子-β₁（TGF-β₁）、白細(xì)胞介素-6（IL-6）、胰島素樣生長(zhǎng)因子1（IGF-1）水平。結(jié)果 治療后，治療組患者的總有效率95.00%比對(duì)照組的83.33%更高（P＜0.05）。治療后，兩組數(shù)字疼痛強(qiáng)度量表（NRS）評(píng)分明顯降低（P＜0.05），且治療組患者NRS評(píng)分較對(duì)照組更低（P＜0.05）。治療后，治療組股骨近端、橈尺骨的骨密度明顯高于治療前（P＜0.05），且治療組股骨近端、橈尺骨的骨密度明顯高于對(duì)照組（P＜0.05）。治療后，兩組的血清BGP、CTX-1水平低于治療前，血清PINP水平高于治療前（P＜0.05）；治療組的血清BGP、CTX-1水平低于對(duì)照組，血清PINP水平高于對(duì)照組（P＜0.05）。治療后，兩組的血清TGF-β₁、IL-6水平低于治療前，血清IGF-1水平高于治療前（P＜0.05）；治療后，治療組的血清TGF-β₁、IL-6水平低于對(duì)照組，血清IGF-1水平高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。結(jié)論 骨疏康顆粒聯(lián)合鹽酸雷洛昔芬片可提高骨質(zhì)疏松癥的療效，有助于降低患者疼痛程度，提高骨密度，改善骨代謝水平，且安全性良好。

Objective To investigate the clinical effect of Gushukang Granules combined with Raloxifene Hydrochloride Tablets in treatment of postmenopausal osteoporosis. Methods Patients (120 cases) with postmenopausal osteoporosis in Luohe Yancheng District Hospital of Traditional Chinese Medicine from January 2021 to December 2022 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Raloxifene Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Gushukang Granules after meals on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the perceived pain level, the bone density of proximal femur and radioulna, and the serum levels of BGP, CTX-1, PINP, TGF-β₁, IL-6, and IGF-1 in two groups were compared. Results After treatment, the total effective rate of 95.00% in the treatment group was higher than 83.33% in the control group (P <0.05). After treatment, the NRS scores of two groups were significantly decreased (P <0.05), and the NRS scores of the treatment group were lower than those of the control group (P <0.05). After treatment, the bone density of the proximal femur and radioulna in the treatment group was significantly higher than before treatment (P < 0.05), and the bone density of the proximal femur and radioulna in the treatment group was significantly higher than that in the control group (P < 0.05). After treatment, the serum levels of BGP and CTX-1 in two groups were lower than before treatment, but the serum levels of PINP were higher than before treatment (P < 0.05). The serum levels of BGP and CTX-1 in the treatment group were lower than those in the control group, but the serum levels of PINP were higher than those in the control group (P < 0.05). After treatment, the serum levels of TGF-β₁ and IL-6 in two groups were lower than before treatment, bute the serum levels of IGF-1 were higher than before treatment (P < 0.05). After treatment, the serum levels of TGF-β₁ and IL-6 in the treatment group were lower than those in the control group, but the serum levels of IGF-1 were higher than those in the control group, with a statistically significant difference (P < 0.05). Conclusion Gushukang Granules combined with Raloxifene Hydrochloride Tablets can improve the efficacy of postmenopausal osteoporosis, help to reduce the pain degree of patients, increase bone density, improve bone metabolism level, with good safety.

R984

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（LHGJ20210965）